ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Voyager Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – VYGR
23 févr. 2021 19h45 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
ROSEN, A LEADING LAW FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
18 févr. 2021 19h10 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
ROSEN, A LEADING AND RANKED FIRM, Encourages Voyager Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline – VYGR
10 févr. 2021 16h28 HE
|
The Rosen Law Firm PA
NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Voyager Therapeutics, Inc. (NASDAQ: VYGR) between June 1,...
Voyager Therapeutics Selects Lead Clinical Candidate for Huntington’s Disease
01 juin 2017 07h04 HE
|
Voyager Therapeutics
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights
09 mai 2017 16h10 HE
|
Voyager Therapeutics
VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
25 avr. 2017 07h02 HE
|
Voyager Therapeutics
Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...
Voyager Therapeutics Provides Second Quarter 2016 Investor Update
11 août 2016 07h05 HE
|
Voyager Therapeutics
VY-AADC01 Phase 1b Study for Advanced Parkinson’s Disease On Track to Report Six-Month Safety, Motor Function, and Biomarker Data from Cohorts 1 and 2 by Year-End 2016 Pipeline Advances with...